2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2016
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infection
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection controlTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIV
2008
Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuse
2007
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug And Alcohol Dependence 2007, 91: 269-278. PMID: 17643869, PMCID: PMC3272856, DOI: 10.1016/j.drugalcdep.2007.06.007.Peer-Reviewed Original ResearchConceptsAtazanavir/ritonavirDrug interactionsMini-Mental State ExaminationOpioid partial agonistPharmacokinetics of atazanavirPharmacokinetics of buprenorphineHIV-negative volunteersEffects of buprenorphineConcentrations of buprenorphineAdverse drug interactionsProtease inhibitor atazanavirAntiretroviral administrationBuprenorphine doseHIV diseaseBuprenorphine treatmentHIV medicationsBuprenorphine/Opioid dependencePharmacodynamic effectsRitonavir concentrationsHealthy controlsOpioid addictionBuprenorphineState ExaminationAtazanavir
2006
Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increaseInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphinePharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedicationsDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine
McCance‐Katz E, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal On Addictions 2006, 15: 23-34. PMID: 16449090, DOI: 10.1080/10550490500419029.Peer-Reviewed Original ResearchConceptsDrug interactionsObjective Opioid Withdrawal ScaleSeven-day study periodNon-nucleoside reverse transcriptase inhibitorMini-Mental State ExaminationOpioid withdrawal symptomsOpioid Withdrawal ScaleClinical pharmacology studiesOpioid-dependent individualsReverse transcriptase inhibitorLAAM treatmentMethadone clearanceOpioid pharmacokineticsOpioid therapyOpioid toxicityAntiretroviral medicationsHIV outcomesPharmacodynamic interactionsCardiac toxicityWithdrawal symptomsAdverse symptomsTranscriptase inhibitorWithdrawal ScaleAcetyl methadolPharmacology studies
2004
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
1999
Tuberculosis and HIV infection
Buitrago M, Friedland G. Tuberculosis and HIV infection. Current Infectious Disease Reports 1999, 1: 105-109. PMID: 11095774, DOI: 10.1007/s11908-999-0017-3.ChaptersProphylaxis of tuberculosisExpert consensus panelAntituberculous regimensAntiretroviral medicationsHIV infectionImportant new recommendationsEquivalent efficacyDrug interactionsConsensus panelShort courseLarge-scale studiesTuberculosisProphylaxisRegimensRifampinTreatmentNew recommendationsMedicationsHIVRifabutinInfectionIndividuals